LCNEC was divided into two independent subtypes, type I was similar to classic SCLC subtype, characterized by alterations in STK11/KEAP1, neuroendocrine phenotype with high expression of ASCL1 and DLL3, down-regulating NOTCH pathway, while type II was characterized by changes in TP53/RB1 displaying predominantly non-neuroendocrine phenotype, with low expression of CgA and Syn, low expression of ASLC1 and DLL3 alongside activation of NOTCH pathway. The gene discussed is TP53; the disease is large cell neuroendocrine carcinoma.